REGENXBIO Statistics
Total Valuation
REGENXBIO has a market cap or net worth of $400.94 million. The enterprise value is $292.28 million.
Important Dates
The next confirmed earnings date is Monday, May 12, 2025, after market close.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
REGENXBIO has 50.12 million shares outstanding. The number of shares has increased by 13.21% in one year.
| Current Share Class | 50.12M |
| Shares Outstanding | 50.12M |
| Shares Change (YoY) | +13.21% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 7.93% |
| Owned by Institutions (%) | 76.14% |
| Float | 41.06M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.47 |
| Forward PS | 1.72 |
| PB Ratio | 1.44 |
| P/TBV Ratio | 1.52 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.51 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.69, with a Debt / Equity ratio of 0.55.
| Current Ratio | 2.69 |
| Quick Ratio | 2.59 |
| Debt / Equity | 0.55 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -18.27 |
Financial Efficiency
Return on equity (ROE) is -79.49% and return on invested capital (ROIC) is -32.24%.
| Return on Equity (ROE) | -79.49% |
| Return on Assets (ROA) | -27.79% |
| Return on Invested Capital (ROIC) | -32.24% |
| Return on Capital Employed (ROCE) | -63.74% |
| Revenue Per Employee | $236,057 |
| Profits Per Employee | -$643,348 |
| Employee Count | 353 |
| Asset Turnover | 0.16 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -48.32% in the last 52 weeks. The beta is 1.11, so REGENXBIO's price volatility has been higher than the market average.
| Beta (5Y) | 1.11 |
| 52-Week Price Change | -48.32% |
| 50-Day Moving Average | 7.37 |
| 200-Day Moving Average | 9.20 |
| Relative Strength Index (RSI) | 50.33 |
| Average Volume (20 Days) | 1,073,075 |
Short Selling Information
The latest short interest is 5.17 million, so 10.31% of the outstanding shares have been sold short.
| Short Interest | 5.17M |
| Short Previous Month | 5.25M |
| Short % of Shares Out | 10.31% |
| Short % of Float | 12.59% |
| Short Ratio (days to cover) | 4.58 |
Income Statement
In the last 12 months, REGENXBIO had revenue of $83.33 million and -$227.10 million in losses. Loss per share was -$4.59.
| Revenue | 83.33M |
| Gross Profit | 49.76M |
| Operating Income | -231.25M |
| Pretax Income | -241.23M |
| Net Income | -227.10M |
| EBITDA | -215.03M |
| EBIT | -231.25M |
| Loss Per Share | -$4.59 |
Full Income StatementBalance Sheet
The company has $234.69 million in cash and $141.72 million in debt, giving a net cash position of $103.15 million or $2.06 per share.
| Cash & Cash Equivalents | 234.69M |
| Total Debt | 141.72M |
| Net Cash | 103.15M |
| Net Cash Per Share | $2.06 |
| Equity (Book Value) | 259.65M |
| Book Value Per Share | 5.24 |
| Working Capital | 174.81M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$173.13 million and capital expenditures -$2.44 million, giving a free cash flow of -$175.56 million.
| Operating Cash Flow | -173.13M |
| Capital Expenditures | -2.44M |
| Free Cash Flow | -175.56M |
| FCF Per Share | -$3.50 |
Full Cash Flow StatementMargins
Gross margin is 59.72%, with operating and profit margins of -277.51% and -272.54%.
| Gross Margin | 59.72% |
| Operating Margin | -277.51% |
| Pretax Margin | -272.54% |
| Profit Margin | -272.54% |
| EBITDA Margin | -258.05% |
| EBIT Margin | -277.51% |
| FCF Margin | n/a |
Dividends & Yields
REGENXBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -13.21% |
| Shareholder Yield | -13.21% |
| Earnings Yield | -57.43% |
| FCF Yield | -44.40% |
Analyst Forecast
The average price target for REGENXBIO is $31.75, which is 296.88% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $31.75 |
| Price Target Difference | 296.88% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 52.85% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
REGENXBIO has an Altman Z-Score of -1.89 and a Piotroski F-Score of 5. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.89 |
| Piotroski F-Score | 5 |